Konstantinos Economopoulos

Dr. Konstantinos Economopoulos


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in JAMA Surgery
Verified
Journal Article
Closed access
PDF file
MMMichael N. Mavros
Michael N. Mavros
KEKonstantinos Economopoulos
Konstantinos Economopoulos
VAVangelis G. Alexiou
Vangelis G. Alexiou
TPTimothy M. Pawlik
Timothy M. Pawlik
Research from JAMA Surgery — Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma — Systematic Review and Meta-analysis

8 April 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
KKKanakaraju Kaliannan
Kanakaraju Kaliannan
SHSulaiman R. Hamarneh
Sulaiman R. Hamarneh
KEKonstantinos Economopoulos
Konstantinos Economopoulos
SASayeda Nasrin Alam
Sayeda Nasrin Alam
OMOmeed Moaven
Omeed Moaven
RHRichard A. Hodin
Richard A. Hodin
Metabolic syndrome comprises a cluster of related disorders that includes obesity, glucose intolerance, insulin resistance, dyslipidemia, and fatty liver. Recently, gut-derived chronic endotoxemia has been identified as a primary mediator for triggering the low-grade inflammation responsible for the development of metabolic syndrome. In the present study we examined the role of the small intestinal brush-border enzyme, intestinal alkaline phosphatase (IAP), in preventing a high-fat-diet–induced metabolic syndrome in mice. We found that both endogenous and orally supplemented IAP inhibits absorption of endotoxin (lipopolysaccharides) that occurs with dietary fat, and oral IAP supplementation prevents as well as reverses metabolic syndrome. Furthermore, IAP supplementation improves the lipid profile in mice fed a standard, low-fat chow diet. These results point to a potentially unique therapy against metabolic syndrome in at-risk humans.

30 January 2014 in Cancer
Verified
Journal Article
Open access
PDF file
CLCarrie C. Lubitz
Carrie C. Lubitz
CKChung Y. Kong
Chung Y. Kong
PMPamela M. McMahon
Pamela M. McMahon
GDGilbert H. Daniels
Gilbert H. Daniels
YCYufei Chen
Yufei Chen
MWMilton C. Weinstein
Milton C. Weinstein
BACKGROUND: Well‐differentiated thyroid cancer (WDTC) is a prevalent disease, which is increasing in incidence faster than any other cancer. Substantial direct medical care costs are related to the diagnosis and treatment of newly diagnosed patients as well as the ongoing surveillance of patients who have a long life expectancy. Prior analyses of the aggregate health care costs attributable to WDTC in the United States have not been reported.METHODS: A stacked cohort cost analysis was performed on the US population from 1985 to 2013 to estimate the number of WDTC survivors in 2013. Incidence rates, and cancer‐specific and overall survival were based on Surveillance, Epidemiology, and End Results (SEER) data. Current and projected direct medical care costs attributable to the care of patients with WDTC were then estimated. Health care–related costs and event probabilities were based on Medicare reimbursement schedules and the literature.RESULTS: Estimated overall societal cost of WDTC care in 2013 for all US patients diagnosed after 1985 is $1.6 billion. Diagnosis, surgery, and adjuvant therapy for newly diagnosed patients (41%) constitutes the greatest proportion of costs, followed by surveillance of survivors (37%), and nonoperative death costs attributable to thyroid cancer care (22%). Projected 2030 costs (in 2013 US dollars) based on current incidence trends exceed $3.5 billion.CONCLUSIONS: Health care costs of WDTC are substantial. Unlike other cancers, the majority of the cost is incurred in the initial and continuing phases of care. With the projected increasing incidence, population, and survival trends, costs will continue to escalate. Cancer 2014;120:1345–1352. © 2014 American Cancer Society.

1 June 2010 in European Journal of Cancer
Verified
Journal Article
Closed access
KEKonstantinos Economopoulos
Konstantinos Economopoulos
Theodoros N. SergentanisTheodoros N. Sergentanis
Theodoros N. Sergentanis

1 March 2011 in Stroke
Verified
Journal Article
Closed access
KEKonstantinos Economopoulos
Konstantinos Economopoulos
Theodoros N. SergentanisTheodoros N. Sergentanis
Theodoros N. Sergentanis
GTGeorgios Tsivgoulis
Georgios Tsivgoulis
AMAnargiros D. Mariolis
Anargiros D. Mariolis
CSChristodoulos Stefanadis
Christodoulos Stefanadis
Background and Purpose—: The comparison between carotid endarterectomy and carotid artery stenting (CAS) remains a debated field, especially in the context of long-term outcomes. Methods—: Concerning the short-term (30-day) analysis, the numbers of outcomes per arm were abstracted, whereas outcomes per arm and hazard ratios were abstracted for long-term (≥1-year) results. Results—: Thirteen randomized trials (3723 carotid endarterectomy and 3754 CAS patients) were eligible. Regarding short-term outcomes, CAS was associated with elevated risk for stroke and “death or stroke.” CAS also exhibited a marginal trend toward higher death and “death or disabling stroke” rates. Carotid endarterectomy presented with higher rates of myocardial infarction and cranial nerve injury. Concerning long-term outcomes, CAS was associated with higher rates of stroke (pooled OR, 1.37; 95% CI, 1.13 to 1.65) and “death or stroke” (pooled OR, 1.25; 95% CI, 1.06 to 1.48). These findings were replicated at the level of pooled hazard ratios and marginally regarding secondary preventive efficacy. The difference in long-term stroke rates was particularly sizeable in patients >68 years, but little difference in rates was observed in those <68 years. No statistically significant heterogeneity became evident. Metaregression did not reveal any significant modifying effect mediated by symptomatic/asymptomatic status, distal protection, early termination of trials, area of study origin, or CAS learning curve. Conclusions—: This meta-analysis points to the significantly less frequent stroke events after carotid endarterectomy at the long-term context. The outcomes of carotid endarterectomy seem superior to CAS, but there may be subgroups, particularly younger patients, in whom the results seem equivalent.

1 February 2017 in International Journal of Surgery
Verified
Journal Article
Closed access
KEKonstantinos Economopoulos
Konstantinos Economopoulos
KMKonstantinos S. Mylonas
Konstantinos S. Mylonas
ASAliki A. Stamou
Aliki A. Stamou
VTVasileios Theocharidis
Vasileios Theocharidis
TSTheodoros N. Sergentanis
Theodoros N. Sergentanis
MRMelanie L. Richards
Melanie L. Richards
The benefit of robotic adrenalectomy (RA) compared to laparoscopic adrenalectomy (LA) is still debatable. The purpose of this paper was to systematically review and synthesize all available evidence comparing RA to LA so as to evaluate which procedure provides superior clinical outcomes. A systematic literature search of PubMed and Scopus databases was performed with respect to the PRISMA statement (end-of-search date: January 31, 2016). Data on perioperative variables were extracted by three independent reviewers. Data were pooled using a random-effects model. Twenty-seven studies were included in this review (13 comparative and 14 non-comparative). Overall, 1162 patients underwent adrenalectomy (747 treated with RA and 415 with LA). There was no significant difference between the robotic and the laparoscopic groups for intraoperative complications (OR: 1.20; 95%CI, 0.33-4.38), postoperative complications (OR: 0.69; 95% CI, 0.36-1.31), mortality (OR: 0.42; 95%CI, 0.07-2.72), conversion to laparotomy (OR: 0.51; 95%CI, 0.21-1.23), conversion to laparotomy or laparoscopy (OR: 0.73; 95%CI, 0.32-1.69) and blood loss (WMD: -9.78; 95%, -22.10 to 2.53). For patients treated with RA, there was a significantly shorter hospital stay (WMD: -0.40; 95% CI, -0.64 to -0.17) and a significantly longer operating time (WMD: 15.60; 95%CI, 2.12 to 29.08). Robotic adrenalectomy is a safe and feasible procedure with similar clinical outcomes as the laparoscopic approach in selected patient populations. High quality RCTs as well as uniform and detailed reporting of outcomes are needed to determine the role and cost-effectiveness of robotic adrenal surgery in the years to come.